ClinicalTrials.gg
RecruitingNCT06740201Updated Jan 27, 2025

A Study to Evaluate the Accuracy of aTCI Model of Cipepofol in Patients With General Anesthesia During Elective Surgery

A Phase 4 interventional study of Cipepofol in Anesthesia, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-01-27.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 4, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 7 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is a multi-center (each center independently conducts the study according to the same research protocol), randomized, and open-label clinical study. The main objective is to verify and optimize the accuracy of the target-controlled infusion model of cipepofol.

Read the detailed description

Subjects who meet the enrollment criteria will be randomly assigned at a 1:1 ratio to two groups with different plasma target-controlled concentrations (Cp) during the induction period: the low-concentration group (Group L) with a concentration of 0.9 μg/ml and the high-concentration group (Group H) with a concentration of 1.2 μg/ml. An interim analysis will be conducted after approximately 5% of the subject data has been collected in each group, including but not limited to indicators such as the effect-site equilibrium rate constant (Ke0).

02

Conditions studied

  • Anesthesia
03

In context

Lead sponsor

Haisco Pharmaceutical Group Co., Ltd. is the lead sponsor of 118 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatient patients scheduled for elective surgeries that require tracheal intubation under general anesthesia, with the expected duration of surgery being ≥ 1 hour, excluding those in emergency, cardiothoracic, or neurosurgery departments (patients whose planned surgical types may affect the collection of the Bispectral Index (BIS) are not eligible for enrollment).
  • Either male or female, aged ≥ 18 and ≤ 65 years old.
  • Classified as grade I - III by the (ASA).
  • (BMI) ≥ 18 and ≤ 30 kg/m².
  • Vital signs during the screening period meet the following criteria:

Respiratory rate ≥ 10 and ≤ 24 breaths per minute. Pulse oxygen saturation (SpO2) ≥ 95% when breathing air. Systolic blood pressure (SBP) ≥ 90 mmHg and ≤ 160 mmHg. Diastolic blood pressure (DBP) ≥ 60 mmHg and ≤ 100 mmHg. Heart rate ≥ 55 and ≤ 100 beats per minute. (Note: The heart rate result of the 12-lead (12-ECG) examination after signing the Form (ICF) shall be used as the basis for judgment.)

● Able to understand the procedures and methods of this study, willing to sign the informed consent form and strictly comply with the trial protocol to complete this study.

Exclusion criteria

Exclusion Criteria:

  • Those with for general anesthesia or a history of previous anesthesia accidents.
  • Those known to be allergic to the of cipepofol injection (soybean oil, glycerol, triglycerides, egg yolk lecithin, sodium oleate and sodium hydroxide), benzodiazepines, opioids, rocuronium bromide, sugammadex sodium and their drug components; those with cross-allergy to halogenated anesthetics, and those who had jaundice and unexplained high fever after using halogenated agents before are prohibited; those with contraindications for propofol.
  • Having the following medical history or evidence that increases the risk of sedation/anesthesia collected before or during the screening:

    1. Cardiovascular history: uncontrolled hypertension or systolic blood pressure (SBP) > 160 mmHg and/or diastolic blood pressure (DBP) > 100 mmHg after treatment with antihypertensive drugs, severe arrhythmia, heart failure, Adams-stokes syndrome, unstable angina pectoris, myocardial infarction occurred within the recent 6 months before screening, a history of tachycardia/bradycardia requiring drug treatment, third-degree atrioventricular block.
    2. Respiratory history: respiratory insufficiency, a history of obstructive pulmonary disease, a history of bronchospasm requiring treatment within 3 months before screening, those who suffered from acute respiratory tract infection within 1 week before the baseline period and had one of the symptoms such as obvious fever, wheezing or expectorant cough.
    3. Neurological and psychiatric history: a history of craniocerebral injury, convulsions, epilepsy, intracranial hypertension, cerebral aneurysm, cerebrovascular accident; or a history of schizophrenia, mania, long-term use of psychotropic drugs, cognitive dysfunction, etc.
    4. Gastrointestinal history: a history of gastrointestinal retention, active bleeding, gastroesophageal reflux or obstruction, etc., and the investigator judges that it may lead to reflux aspiration.
    5. Diabetic patients with unsatisfactory blood glucose control (fasting blood glucose ≥ 11.1 mmol/L or random blood glucose ≥ 13.6 mmol/L).
    6. Having a history of diseases in the liver, kidney, blood system, nervous system or metabolic system that are not controlled and are judged by the investigator as not suitable for participating in this study and have significant clinical significance.
    7. A history of alcohol abuse within 3 months before screening.
    8. A history of drug abuse within 3 months before screening.
    9. Those who had severe infection, severe trauma or major surgical operations within 4 weeks before screening.
  • Having any of the following risks in airway management before or during the screening:

    1. A history of asthma, wheezing.
    2. Those with sleep apnea syndrome.
    3. Those with a history or family history of malignant hyperthermia.
    4. Those with a history of failed tracheal intubation.
    5. The investigator judges that there is a difficult airway or it is determined as difficult tracheal intubation (modified Mallampati score is grade III or IV).
  • Having used any of the following drugs or treatments before anesthesia induction:

    1. Those who participated in any drug clinical trials within 1 month before screening.
    2. Those who used propofol, other general sedative/anesthetic drugs and/or opioid analgesics or compound preparations containing opioid analgesic components within 4 hours before anesthesia induction.
  • Laboratory examination indexes during the screening period meet the following standards and are confirmed by reexamination:

    1. \< 1.5 × 10⁹/L.
    2. count \< 80 × 10⁹/L.
    3. \< 90 g/L (and without blood transfusion within 14 days).
  • Pregnant and lactating women; fertile women or men who are unwilling to use during the entire trial period; subjects (including male subjects) who have a pregnancy plan within 3 months after the trial.
  • Subjects who are considered by the investigator to have any other factors that are not suitable for participating in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Cp=0.9μg/ml

    Plasma target-controlled concentration 0.9μg/ml

    Drug: Cipepofol

  • Experimental
    Cp=1.2μg/ml

    Plasma target-controlled concentration 1.2μg/ml

    Drug: Cipepofol

Interventions

  • Adjust plasma target-controlled concentration

    Also known as: HSK3486

06

What researchers measure

Primary outcomes

  1. Optimize the parameters CeLoC/CeRoC and Ke0 of the target-controlled infusion model of cipepofol.

    Calculate/record the effect-site concentrations of ciprofol (CeLoC/CeRoC) at the time of loss of consciousness (LoC) and recovery of consciousness (RoC), as well as the effect-site equilibrium rate constant (Ke0). The units of CeLoc and CeRoc is μg/ml. Calculate Ke0 through computer simulation based on the pharmacokinetic parameters.

    Time frame: 2 h

07

Study locations

1 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Ce and Cp parameters

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Mar 2025, 2 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2024
First posted
Dec 18, 2024
StartActual
Jan 6, 2025
Primary completionEst.
Mar 30, 2025
CompletionEst.
May 30, 2025
Last update
Jan 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06740201
Responsible party
Sponsor
First posted
Dec 18, 2024
Start date
Jan 6, 2025
Primary completion
Mar 30, 2025 (estimated)
Completion
May 30, 2025 (estimated)
Last update
Jan 27, 2025

Study contacts

Gao Jingui, Doctor
Contact
gaojingui@126.com
15803210586
Gao Jingui, Doctor
principal investigator · Investigator

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ciprofol

Start the discussion